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BACKGROUND Patients with chronic kidney disease (CKD) have a
higher risk of cardiovascular disease than those without it. Limited
studies, however, have addressed an impact of CKD on clinical out-
comes in a large cohort of patients with acute myocardial infarction
(AMI) deﬁned as elevated cardiac troponin.
METHODS A total of 3,281 patients presenting with AMI were enrolled
in the J-MINUET study, which is a prospective, multicenter registry in
Japan (UMIN000010037). AMI was diagnosed based on the latest
universal deﬁnition. CKD stage on admission was classiﬁed into 3
groups (stages 1 or 2, eGFR 60mL/min/1.73m2; stage 3,
60>eGFR30mL/min/1.73m2; and stages 4 or 5, eGFR<30mL/min/
1.73m2). We assessed odds ratio (OR) of CKD stages having in-hospital
mortality or major adverse cardiac event (MACE) deﬁned as a com-
posite of all-cause death, cardiac failure, fatal arrhythmia and major
bleeding during hospitalization. To assess the performance of CKD
stages in predicting in-hospital mortality or MACE, C-index and net
reclassiﬁcation improvement (NRI) were also calculated.
RESULTS Median age was 69 (61-78) years and 75.2% of patients
were male. Of the 3,281 patients, 1,878 had CKD stages 1 or 2, 1,073
had CKD stage 3 and the remaining 330 had CKD stages 4 or 5. While
in-hospital mortality signiﬁcantly increased from 2.0% in CKD stages
1 or 2 through 9.6% in CKD stage 3 to 21.5% in CKD stages 4 or 5
(p<0.0001), MACE also signiﬁcantly increased from 6.8% in CKD
stages 1 or 2 through 4.8% in CKD stage 3 to 39.5% in CKD stages 4 or
5 (p<0.0001). Crude and adjusted OR for in-hospital mortality were
5.14 (3.54-7.60) and 2.00 (1.23-3.28) in CKD stage 3, and 13.3 (8.82-
20.3) and 6.71 (3.91-11.7) in CKD stage 4 or 5 as compared to CKD
stages 1 or 2. Crude and adjusted OR for in-hospital MACE were 3.73
(3.05-4.57) and 1.67 (1.29-2.18) in CKD stage 3, and 5.98 (4.56-7.82)
and 2.82 (1.96-4.02) in CKD stage 4 or 5 as compared to CKD stages 1
or 2. C-index of basic model was 0.877 (0.849-0.904) and signiﬁ-
cantly gained up to 0.890 (0.862-0.919) when adding CKD stage to
this model in predicting in-hospital mortality (p¼0.04; NRI 0.627,
p<0.0001). Similarly, C-index of basic model was 0.820 (0.798-0.842)
and signiﬁcantly gained up to 0.830 (0.808-0.851) when adding CKD
stage to this model in predicting in-hospital MACE (p¼0.011; NRI
0.306, p<0.0001).
CONCLUSIONS Our results indicated that the presence of CKD was
independently associated with in-hospital mortality and MACE in
patients with AMI. Evaluation of CKD stage would be useful to predict
in-hospital mortality and MACE in AMI.
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BACKGROUND The utility of currently validated risk prediction
models of ST-elevation myocardial infarction (STEMI) is limited by
their complexity. We aimed to evaluate a simpliﬁed risk tool to
identify high and low-risk STEMI patients and assess the impact of
door-to-balloon-times (DTBT) on their long-term mortality.
METHODS We analyzed baseline clinical and procedural character-
istics of 2,539 consecutive STEMI patients who underwent primary
percutaneous coronary intervention (PCI) from the Melbourne
Interventional Group registry from 2004-2011. Patients were classi-
ﬁed high risk (HR-STEMI) if they presented with cardiogenic shock,
out of hospital cardiac arrest (OHCA) or Killip class 2; or low-risk
(LR-STEMI) if there were no high-risk features. We further stratiﬁed
patients by DTBT (90 minutes vs. >90 minutes) and determined
the long-term mortality in high and low risk patients stratiﬁed by
DTBT.
RESULTS Of the 2,539 patients, 395 (16%) met the high-risk criteria. A
DTBT 90 minutes was achieved in 43% of HR-STEMI patients and in
55% of LR-STEMI patients. Patients in the HR-STEMI compared to LR-
STEMI cohort had higher in-hospital (31% vs. 1%, p<0.01) and long-
term mortality (37% vs. 7%, p<0.01). A DTBT 90 minutes was asso-
ciated with signiﬁcant improvements in short and long-term mortality
in both groups. A DTBT 90 minutes was an independent multivariate
predictor of long-term survival in LR-STEMI (hazard ratio [HR] 0.5,
95% conﬁdence interval [CI] 0.3-0.9, p¼0.02) but not in HR-STEMI
(HR 0.7, 95% CI 0.5-1.1, p¼0.11).
CONCLUSIONS A simpliﬁed clinical tool incorporating cardiogenic
shock, OHCA or Killip class 2 clearly identiﬁes a cohort with signif-
icantly worse prognosis. Timely reperfusion is associated with
improved outcomes in both cohorts. Paradoxically, achieving a
DTBT 90 minutes appears to be prognostically more important in LR-
STEMI patients.
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BACKGROUND Concomitant use of proton pump-inhibitor (PPI) with
clopidogrel has been reported to be associated with increased risk of
mortality and myocardial infarction in patients receiving coronary
intervention due to drug interaction. There is little data in large
populations.
METHODS We have conducted a meta-analysis of published and un-
published studies including patients with acute coronary syndrome or
stable angina receiving coronary stenting discharged on clopidogrel,
Data source was MEDLINE(ovid), PubMed, Web of Science, Cochrane
Central Register of Controlled Trials and Science Direct from 1950 to
November 2009 with English language. Using standardized protocol, 2
reviewed serially abstracted data from each study.
RESULTS Four published and 3 unpublished studies with information
on 43432 patients and 7354 events were included. Common primary
outcomes were death including cardiovascular cause, myocardial
infarction, stroke. The pooled odd ratio (OR) was 1.56 (95% CI. 1.28-
1.89), with signiﬁcant heterogeneity across studies (I2¼86.3%,
p<0.001). This heterogeneity was due to the different estimation be-
tween published and unpublished studies: OR, 1.39(CI, 1.04-1.87) and
2.19 (CI, 1.25-3.83), respectively.
